Sign in now to see personalised content appear here.
You can also see your reading history and subscription details on your subscriber page.
Instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and biomarker validation are in demand, reports Kalorama
Company expands its state-of-the-art healthcare manufacturing facility at Cimanggis with €8.1m investment
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Company announces additional investment in facilities to develop new drugs
The agreement is designed to provide greater access to the extensive depth and breadth of Rosa's expertise and foster enhanced adoption of the PhysioPD platform
Huge quantities of aggregated research and real-patient information may hold important keys for future drug discovery. Jaqui Hodgkinson, Elsevier R&D Solutions, looks at the benefits and challenges of harnessing meaningful information quickly and cost-effectively from big data
To study extracellular vesicle yields from different cell culture lines
Next-Generation Sequencing is revolutionising the study of genomics and molecular biology. Thermo Fisher Scientific explains how it can be used in the design of therapeutic products with a future goal of enabling precision oncology
Suitable for a number of applications including pharmacy compounding, small-scale potent material handling and aseptic processing
In addition to proof of drug effectiveness, pharmacovigilance has become an important safety requirement laid down by the regulators. Dr Chitra Lele, CSO, Sciformix Corporation, discusses the importance of establishing an effective global safety framework to meet today’s needs
If draft legislation goes ahead, pharmaceutical companies will need to tread carefully, says IP law firm Withers & Rogers
With R&D and production costs spiralling and the growing regulatory requirements biting into the profit margins of drug sales, the industry needs radical change to manufacturing models, argues Ed Price, President, PCI Synthesis